Enfortumab Vedotin/Pembrolizumab May Be New SOC in Frontline Urothelial Cancer
For the first time, a new therapeutic regimen outperformed chemotherapy in improving overall survival in frontline urothelial cancer.
Bisphosphonates May Reduce Fracture Risk in Patients With Metastatic Hormone-Sensitive Prostate Cancer
A database analysis showed that zoledronic acid led to a 64% reduction in fracture risk among patients with metastatic hormone-sensitive prostate cancer.
Women Who Receive Organ-Sparing Robotic Cystectomy Experience Preserved Sexual, Urinary Function
A retrospective study presented at the 22nd SUO Annual Meeting revealed that pelvic organ–preserving robot-assisted radical cystectomy allowed women to return to sexual activity post-surgery.
PSA Screening Leads to Better Outcomes in Young African Americans
There is an association between increased prostate-specific antigen (PSA) screening and improved outcomes in younger African American patients.
YouTube Videos Spread Cancer Misinformation
Studies found that misinformation and bias is prevalent in YouTube videos about prostate and bladder cancer.
FDA Approves Atezolizumab for PD-L1 High NSCLC
The FDA has approved the single-agent atezolizumab as a first-line treatment for patients with metastatic non-small cell lung cancer who have a high PD-L1 expression and no EGFR or ALK genomic tumor aberrations.
Dasatinib Approved for Pediatric Ph+ Chronic Phase CML
Dasatinib (Sprycel) has been approved by the FDA to treat pediatric patients with Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML) in chronic phase (CP).
Neoadjuvant Pembrolizumab Improves pCR Across ER+ Breast Cancer Subgroups
Tucatinib Continues to Show Benefit in Pretreated HER2+ Breast Cancer With Brain Metastases
Ribociclib Plus Endocrine Therapy Continues to Perform Well Across MONALEESA-2, -3, and -7 Trials
Patient-Reported Outcomes From CAPItello-291 Trial Support Capivasertib/Fulvestrant in HR+, HER2- Advanced Breast Cancer
2 Clarke Drive Cranbury, NJ 08512